CJC-1295 DAC Dosage

Peptides are playing a growing role in scientific research due to their wide range of biological functions. A notable example is CJC-1295 DAC (Drug Affinity Complex), a synthetic version of (GHRH) growth hormone-releasing hormone. Researchers are particularly interested in CJC-1295 DAC because it may help boost growth hormone (GH) levels by prolonging the activity of naturally produced GHRH.

While most studies have focused on its hormonal effects, scientists also explore its broader impact on other bodily systems and its potential applications in experimental and investigative research.

CJC-1295 DAC Dosage Chart

Research Purpose	Weekly Dosage	Typical Frequency	Notes / Study Duration
General Health / Anti-Aging	1 – 2 mg	Once weekly	Supports GH and IGF-1 maintenance; long-term studies (e.g., chronic wellness).
Fat Metabolism / Body Comp	1 – 2 mg (titrated)	Once weekly	Often paired with diet/exercise; duration varies.
Muscle Growth / Recovery	2 – 3 mg	Once weekly or split	Used in athletic studies; longer-term (e.g., 16–20 weeks).
Tissue Healing / Injury Repair	~2 mg	Once weekly	Shorter duration studies; focus on muscle/tendon regeneration.
Performance Enhancement	2 – 3 mg	Split into 2 doses/week	16–20 week protocols; measured for strength and endurance gains.

What is CJC-1295 DAC?

CJC-1295 is a lab-created peptide that helps the body boost its growth hormone production. Rather than delivering growth hormone directly, it imitates a naturally occurring hormone called GHRH (growth hormone-releasing hormone). This stimulates the pituitary gland to release growth hormone in natural pulses—similar to when you’re younger or getting restful sleep. By working with the body’s rhythm, CJC-1295 supports hormone balance instead of disrupting it, reducing the risk of side effects from injecting synthetic growth hormone.

CJC-1295 is available in two main forms: one with DAC (Drug Affinity Complex) and one without. The DAC version stays active in the body longer—sometimes up to a week with just one dose. This makes it a more convenient option for those looking for sustained hormone support with fewer injections. The version without DAC, often known as Mod GRF 1-29, has a shorter effect window and is designed to more closely mimic the body's natural release patterns. While both have their advantages, the longer-lasting DAC version is often preferred for its consistency and ease of use in long-term protocols.

The use of CJC-1295 DAC

Hormonal and Metabolic Research

CJC-1295 DAC has drawn growing interest in research circles due to its ability to boost growth hormone levels, especially in the context of how hormones influence metabolism. Because growth hormone plays a role in how the body handles fats, some researchers believe this peptide could be useful for studying how fat is broken down (lipolysis) and stored (lipogenesis). In lab studies, compounds like CJC-1295 DAC have been used to explore how changes in natural growth hormone signals might affect how the body burns fat and uses energy. These studies could help us better understand metabolic conditions like obesity or type 2 diabetes, where fat processing in the body goes awry.

Another area of interest is how CJC-1295 DAC might affect glucose metabolism. Growth hormone is closely tied to the IGF-1 pathway, influencing how the body handles sugar. Early research indicates that boosting growth hormone might improve insulin sensitivity, making CJC-1295 DAC a potential tool for studying insulin-related conditions. By adjusting GH and IGF-1 levels, this peptide could help scientists learn more about how the body uses glucose, stores glycogen, and responds to insulin—information that may be valuable for tackling diseases linked to poor blood sugar control.

Cellular and Tissue Research

Researchers are studying CJC-1295 DAC as a candidate for research into how cells grow and rebuild tissue. This is mainly due to its link to IGF-1, a growth factor known to help cells grow and multiply. IGF-1 is already known to play a role in muscle growth, wound repair, and tissue rebuilding. Because CJC-1295 DAC can raise growth hormone and IGF-1 levels, scientists believe that it might play a role in helping these regenerative processes—potentially making it useful in areas like tissue engineering and repair research.

Research in the lab also suggests that the peptide could be useful in studying how muscle tissue repairs after injury. This could apply to trauma healing or disease where muscle breakdown is a factor. Interest also lies in whether or not CJC-1295 DAC would affect collagen synthesis in parts of the body like the skin or connective tissues. These elements are important in healing and structure, so this peptide could hold the key to tissue repair far beyond muscle—potentially leading to regenerative medicine breakthroughs.

Cellular Aging

Researchers are studying the hypothesis that CJC-1295 DAC could help overcome some of the components of aging on a cellular level. Over time, the body's natural secretion of growth hormone and IGF-1 slows down. Their deficiency correlates with reduced tissue recovery, higher fat production, and lower muscle mass. By maintaining GH and IGF-1 levels above normal in test models, researchers are exploring the possibility that CJC-1295 DAC can slow or halt some of the changes in the body with advancing age.

Cardiovascular Health

Heart and blood vessel well-being is yet another area being explored for potential research on CJC-1295 DAC. Growth hormone and IGF-1 have been shown to ensure the structure and function of the cardiovascular system remain intact. Research shows that CJC-1295 DAC can play a role in keeping these hormones in check, which could be beneficial for cardiovascular health, help with healing blood vessels, or even regulate blood pressure. More interest is growing in how this peptide can benefit overall cardiovascular function and assist with more positive results in related health conditions.

Brain Health

This is a field of growing interest in the influence of growth hormone and IGF-1 on the brain that has scientists studying drugs like CJC-1295 DAC in neuroscientific research. Since GH receptors are found in a large part of the brain and IGF-1 is linked to processes like neurogenesis, memory, and learning, scientists are interested in knowing how this peptide can boost brain function. The premise is that CJC-1295 DAC will help impact these pathways, making it a worthy tool for assessing neurological health and age-related cognitive impairment.

A number of scientists also see the potential for using this peptide to explore treatments for neurodegenerative conditions such as Alzheimer's or Parkinson’s, where growth hormone and IGF-1 signaling are typically diminished. By studying how CJC-1295 DAC might affect brain plasticity, memory, and the functioning of nerve cells, scientists are looking to better understand the root causes of these diseases. Its efficacy at keeping GH levels stable might also offer a new approach for research into how hormonal balance influences long-term brain health and resistance to decline.

Bone Health

Because growth hormone plays a crucial role in bone repair and growth, CJC-1295 DAC has been of interest to skeletal health research. Growth hormone can possibly augment bone growth by increasing the activity of osteoblasts—the bone cells responsible for building new bones. IGF-1 also augments bone and cartilage function. Researchers are particularly interested in whether this peptide could increase bone density or speed fracture or osteoporosis healing.

Other researchers have suggested that CJC-1295 DAC could be useful in examining how sustained growth hormone activity affects the remodeling of the skeletal tissue, especially where bone mass is lost. By observing its effects on bone-building (osteoblast) and bone-breakdown (osteoclast) cells, researchers could gain further insight into the biological process of bone construction and repair. Its effect on cartilage has also generated interest, potentially rendering it useful for treating joint diseases like osteoarthritis.

Dosage Calculator

When it comes to research studies involving CJC-1295 DAC, dosing protocols could vary depending on what the researchers want to target. The peptide can be cycled weekly since it has a long half-life and lasts weeks in the body.

Scientists usually use a lower dose, ranging from 1 to 2 milligrams per week for overall health or anti-aging treatment. This dosage is usually meant to help chronically maintain healthy growth hormone and IGF-1 levels.

In body composition or fat metabolism research, the dose usually remains in the same dosage range—1 to 2 milligrams per week—but is sometimes titrated to subject response. These studies generally test whether and how CJC-1295 DAC might contribute to fat loss when combined with exercise and diet.
When the intention is to grow muscles or aid in athletic recovery, dosages are sometimes increased—usually 2 to 3 milligrams weekly. Such a protocol may be part of longer-duration research that measures gains in muscle mass or enhancements in strength over a few months.

For the healing of tissues or recovery from injury, studies usually administer doses in the vicinity of 2 milligrams per week, sometimes adjusted for a shorter duration. This could be focused on observing how the peptide facilitates recovery in muscles, tendons, or other tissues.
Some performance-based studies take 16 to 20 weeks, using doses similar to bulking regimens. In some cases, the weekly dose is split into two lower injections to maintain stable levels in the system.

In general, CJC-1295 DAC is delivered subcutaneously most often, and because of its longer action, weekly injections will typically be sufficient. Researchers store the reconstituted peptide in the refrigerator to provide stability throughout the study.

Conclusion

This peptide is the least complicated and works with your body, not against it. CJC-1925 DAC acts as a biological switch without overwhelming your body’s hormonal balance, leading to faster recovery, tissue repair, fat metabolism, and muscle growth while maintaining a strong safety profile.
Considering that this peptide has minimal side effects, it proves that the smartest enhancements are the ones that help your body work smarter, not harder.

References:

1. Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797. https://doi.org/10.1210/jc.2006-1702
2. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.-P., & Frohman, L. A. (2006). Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting GHRH analog, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
3. Gagnon, C., Castaigne, J.-P., Labrie, F., & Bélanger, A. (2004). Long-acting growth hormone-releasing hormone analog CJC-1295 enhances GH and IGF-I secretion in healthy men. Growth Hormone & IGF Research, 14(5), 384–391. https://doi.org/10.1016/j.ghir.2004.06.001
4. Evans, W. S., Patrie, J. T., Kaiser, D. L., et al. (2001). Continuous subcutaneous infusion of growth hormone-releasing peptide-2 and CJC-1295 stimulates GH release in humans. The Journal of Clinical Endocrinology & Metabolism, 86(6), 3039–3044. https://doi.org/10.1210/jcem.86.6.7578
5. Teichman, S. L., Castaigne, J.-P., Gagnon, C., et al. (2005). Single-dose administration of CJC-1295, a long-acting GHRH analog, results in dose-dependent increases in GH and IGF-I in healthy adults. Clinical Pharmacology & Therapeutics, 78(3), 228–239. https://doi.org/10.1016/j.clpt.2005.05.009
6. Gagnon, C., & Castaigne, J.-P. (2003). Pharmacokinetics and pharmacodynamics of CJC-1295 in healthy men. Hormone Research, 60(Suppl. 1), 90–97. https://doi.org/10.1159/000071876
7. Frohman, L. A., & Jansson, J. O. (2009). Growth hormone-releasing hormone analogs: Clinical applications and safety profile. Pituitary, 12(3), 236–244. https://doi.org/10.1007/s11102-008-0137-3